The proposed “transcribrial route” would offer clear benefits over the conventional intravenous route, in that it would enable the use of water soluble drugs [9] to attain MIC at the epicenter of infection, overcome the BBB hindrance, minimal adverse effects by enjoying the benefits of topical administration and dose adjustment at a faster pace. Given that PAM patients are receiving adjuvant therapies including anti-seizure, strong hypnotics, and even general anesthetics (9), patient compliance with the proposed route should not pose any concern. Further research will test the effectiveness of the proposed “transcribrial route” to administer drugs in the management of PAM due to N. fowleri and possibly other pathogens causing brain infections.